Post-cycle and ancillaries compared

Clomid vs enclomiphene

A mixture of two isomers and one of those isomers on its own, with each figure tied to its own source.

Clomiphene citrate is a mixture of two geometric isomers, zuclomiphene (cis) and enclomiphene (trans), and enclomiphene is the trans isomer on its own.1 The Clomid label states that zuclomiphene has a longer half-life than enclomiphene, and a phase II report cites a serum half-life of about 7 hours for enclomiphene from earlier work.1,2

Clomid is a US-labelled 50 mg tablet for ovulatory dysfunction in women desiring pregnancy, and the European Medicines Agency refused a marketing authorisation for the enclomiphene medicine EnCyzix in 2018.1,3

FactClomiphene (Clomid)Enclomiphene
What it isA mixture of zuclomiphene (cis) and enclomiphene (trans), with 30% to 50% of the cis isomer1The trans isomer of clomiphene citrate, given as 62% of it in a trial report2
How it comesTablets of 50 mg clomiphene citrate, taken by mouth1Taken by mouth in its trials, as capsules in the phase II trial2,6
Half-life
  • US label: zuclomiphene has a longer half-life than enclomiphene, and detectable zuclomiphene persisted for longer than a month1
  • A single-dose study in 9 patients could not determine it, citing a very flat terminal half-life7
About 7 hours, cited from earlier work in a phase II report's discussion2; FDA's presentation to its compounding committee gives 10 hours8. In the trial, serum levels were not back to baseline 24 hours after a dose2
Studied doses
  • US label: 50 mg daily for 5 days, then a second course of 100 mg daily for 5 days if ovulation does not occur1
  • One trial in a review of trials in men: 50 mg a day against placebo for 12 weeks9
  • Phase II trial: 6.25, 12.5 or 25 mg daily by mouth for 6 weeks, against transdermal testosterone2
  • Phase III trials: daily oral doses for 16 weeks, against testosterone gel6
StatusUS label: ovulatory dysfunction in women desiring pregnancy; no adequate studies show effectiveness in male infertility1. WADA names clomifene under S4.2, prohibited at all times10The European Medicines Agency refused a marketing authorisation for EnCyzix (enclomifene) in 2018, citing a risk of venous thromboembolism (blood clots in the veins) and studies that did not look at symptoms3. FDA proposed to its compounding committee that it not go on the 503A bulks list11

Get the app

Contents6
  1. 1The study that compared them
  2. 2How they differ
  3. 3Logged in Milligram
  4. 4What is not known
  5. 5References
  6. 6Related pages

Last reviewed . Sources are listed below.

The study that compared them

A retrospective study of 66 men given clomiphene and, later, enclomiphene for hypogonadism reported adverse effects in 47% on clomiphene and 13.8% on enclomiphene.4 The median change in testosterone was 98 ng/dL on clomiphene, measured from before clomiphene, and 166 ng/dL on enclomiphene, measured from the level reached on clomiphene (P=0.20, not statistically significant); the authors name the absence of a washout period as a limitation.4

How they differ

The Clomid label states that some data suggest zuclomiphene has greater estrogenic activity than enclomiphene.1 In 15 men taking clomiphene 25 mg daily, the median serum level was 44.0 ng/mL for zuclomiphene and 2.2 ng/mL for enclomiphene.5

Logged in Milligram

  • Clomiphene (Clomid): Too few people logged it to show a share.
  • Enclomiphene: Too few people logged it to show a share.

Shares of people who logged a dose in Milligram in the 90 days to 15 November 2026, shown only where at least 50 people logged three or more doses of the compound.

What is not known

The European Medicines Agency's overview states that the main studies did not look at whether EnCyzix would improve symptoms such as bone strength, weight gain, impotence and libido, and that there is a risk of venous thromboembolism with the medicine.3 The Clomid label states that the cause and effect relationship between reports of testicular tumors and clomiphene is not known.1

References

  1. Cosette Pharmaceuticals, Inc. Clomid (clomiphene citrate) tablets, USP: prescribing information. Drug label, 2023. DailyMed label
  2. Wiehle R, Cunningham GR, Pitteloud N, et al. Testosterone restoration using enclomiphene citrate in men with secondary hypogonadism: a pharmacodynamic and pharmacokinetic study. Phase II trial, 2013. PMC4155868
  3. European Medicines Agency. EnCyzix (enclomifene): refusal of marketing authorisation, overview. Regulator page, 2018. ema.europa.eu
  4. Saffati G, Kassab J, Orozco Rendon D, et al. Safety and efficacy of enclomiphene and clomiphene for hypogonadal men. Retrospective study, 2024. PMC11491226
  5. Helo S, Mahon J, Ellen J, et al. Serum levels of enclomiphene and zuclomiphene in men with hypogonadism on long-term clomiphene citrate treatment. Observational study, 2017. PMID 27511863
  6. Kim ED, McCullough A, Kaminetsky J. Oral enclomiphene citrate raises testosterone and preserves sperm counts in obese hypogonadal men, unlike topical testosterone: restoration instead of replacement. Phase III trials, 2016. PMID 26496621
  7. Ghobadi C, Mirhosseini N, Shiran MR, et al. Single-dose pharmacokinetic study of clomiphene citrate isomers in anovular patients with polycystic ovary disease. Pharmacokinetic study, 2009. PMID 19033451
  8. US Food and Drug Administration. Pharmacy Compounding Advisory Committee meeting transcript, 8 June 2022 (enclomiphene citrate topic). 2022. fda.gov
  9. Hohl A, Chavez MP, Pasqualotto E, et al. Clomiphene or enclomiphene citrate for the treatment of male hypogonadism: a systematic review and meta-analysis of randomized controlled trials. Systematic review and meta-analysis, 2025. PMC12510335
  10. World Anti-Doping Agency. The Prohibited List 2026. Prohibited List, 2026. wada-ama.org
  11. US Food and Drug Administration. Final summary minutes of the Pharmacy Compounding Advisory Committee meeting, 8 June 2022. Regulator minutes, 2022. fda.gov